Q3 EPS Estimate for TriSalus Life Sciences Cut by Analyst

Key Points

• Northland Capital Markets has lowered its Q3 2025 earnings estimate for TriSalus Life Sciences to ($0.19) per share, down from a previous estimate of ($0.18).
• TriSalus reported Q2 earnings of ($0.27) per share, missing analyst consensus estimates by ($0.05), despite generating $11.21 million in revenue, which surpassed expectations.
• Insider Richard Marshak sold 6,597 shares of TriSalus stock, representing an 8.71% reduction in ownership, as the company experienced a recent stock price decline of 1.8%.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Analysts at Northland Capmk decreased their Q3 2025 EPS estimates for TriSalus Life Sciences in a research note issued on Wednesday, August 13th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings of ($0.19) per share for the quarter, down from their previous estimate of ($0.18). The consensus estimate for TriSalus Life Sciences' current full-year earnings is ($1.55) per share. Northland Capmk also issued estimates for TriSalus Life Sciences' Q4 2025 earnings at ($0.16) EPS.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The business had revenue of $11.21 million for the quarter, compared to analyst estimates of $10.69 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS.

TriSalus Life Sciences Price Performance

Shares of NASDAQ:TLSI traded up $0.2040 during midday trading on Friday, hitting $4.8540. The company had a trading volume of 39,970 shares, compared to its average volume of 62,570. TriSalus Life Sciences has a 12-month low of $3.42 and a 12-month high of $5.88. The company has a fifty day moving average of $4.75 and a two-hundred day moving average of $5.20. The company has a market cap of $183.68 million, a price-to-earnings ratio of -4.11 and a beta of 0.48.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Police & Firemen s Retirement System of New Jersey purchased a new position in TriSalus Life Sciences during the second quarter valued at approximately $29,000. JPMorgan Chase & Co. lifted its stake in shares of TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company's stock valued at $41,000 after buying an additional 7,519 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in TriSalus Life Sciences in the 2nd quarter worth $47,000. Charles Schwab Investment Management Inc. purchased a new stake in TriSalus Life Sciences in the 1st quarter worth $55,000. Finally, Renaissance Technologies LLC bought a new stake in TriSalus Life Sciences during the fourth quarter valued at about $67,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.